Allergy Therapeutics plc (AGYTF)
OTC PINK OTC PINK Primary Summary
AGYTF Chart
Cavendish stays positive on Allergy Therapeutics as attention turns to key 2026 decision
Cavendish has reiterated its 13p target price on Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) after the company posted full-year results that were broadly in line with guidance and reflected a period of transition in its largest market. Revenue for the year to June 2025 came in at £55 million, effectively flat on last year but up about 2% at constant exchange rates.
Allergy Therapeutics steadies finances as it eyes Hong Kong listing
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has posted broadly steady annual results and outlined plans that point to a busier year ahead, including the possibility of a second stock market listing in Hong Kong. The biotechnology group, which develops treatments designed to reduce sensitivity to common allergens such as grass pollen and peanuts, reported revenue of £55 million for the year to 30 June, almost unchanged from the previous year's £55.2 million.
Allergy Therapeutics hits key safety milestone in peanut allergy study
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has cleared an important hurdle in the early testing of its experimental peanut allergy treatment, saying the highest planned dose in its PROTECT study has proved safe and well tolerated. The phase I/IIa trial has now completed dosing of the minimum required number of participants at that top dose, meeting its primary safety endpoint.
Allergy Therapeutics plc (AGYTF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Allergy Therapeutics plc ever had a stock split?
Allergy Therapeutics plc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Manuel Llobet CEO | OTC PINK Exchange | GB00B02LCQ05 ISIN |
| GB Country | 612 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Allergy Therapeutics plc is a pioneering commercial biotechnology entity focused on the research, development, and commercialization of innovative treatments for allergies. The company operates with a commitment to enhancing the quality of life for individuals suffering from various allergic conditions, leveraging cutting-edge scientific research to address the unmet needs in this medical domain. Since its inception in 2004, Allergy Therapeutics plc has established a significant presence not only within the United Kingdom but also across Central and Southern Europe, alongside a growing international footprint. The company's headquarters are situated in Worthing, the United Kingdom, serving as a hub for its operations and advancements in the field of allergology.
Products and Services
Pollinex Quattro: A line of injectable allergen-specific immunotherapies, designed to address pollen-related allergies with a focus on grasses, weeds, and trees, leveraging a short-course treatment methodology for effective allergy mitigation.
Oralvac: A comprehensive sublingual immunotherapy solution aimed at treating a wide range of pollen-related allergies. This product underscores the company's dedication to providing patient-friendly, non-invasive treatment options.
Venomil: Specialized injectable immunotherapies targeted at treating venom-induced allergies, providing critical care for individuals with severe reactions to insect stings.
Venom ATL Polistes Dominula: A specific treatment solution for allergies caused by the stings of the Polistes Dominula wasp, reflecting the company's commitment to addressing niche and potentially life-threatening allergic reactions.
Acarovac Plus: A distinctive immunotherapy option designed for individuals allergic to house dust mites, offering a path towards long-term relief from this pervasive allergen.
Pollinex: The fundamental line of injectable allergen-specific immunotherapies developed by Allergy Therapeutics plc, providing a cornerstone treatment for various pollen-related allergies.
Synbiotics: Products that focus on the role of gut health in allergic diseases, offering a novel approach to allergy management through the modulation of the microbiota.
VLP Peanut: An advanced vaccine candidate aimed at combating peanut allergies, utilizing virus-like particles (VLPs) to provide a highly targeted immune response, showcasing the company's innovation in addressing food allergies.
In addition to these flagship products, Allergy Therapeutics plc is actively involved in the development of novel vaccine solutions for a range of allergens, including pollen, house dust mites, animal fur, and food allergies, particularly peanuts. This diverse product portfolio exemplifies the company's dynamic approach to allergy treatment, encompassing both traditional and cutting-edge methodologies to cater to the variegated needs of allergy sufferers worldwide.
Contact Information
